- Home
- MESO vs RAMP Comparison
MESO vs RAMP Comparison
Compare MESO & RAMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- RAMP
- Stock Information
- Founded
- MESO 2004
- RAMP 2018
- Country
- MESO Australia
- RAMP United States
- Employees
- MESO N/A
- RAMP N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- RAMP EDP Services
- Sector
- MESO Health Care
- RAMP Technology
- Exchange
- MESO Nasdaq
- RAMP Nasdaq
- Market Cap
- MESO 2.0B
- RAMP 2.0B
- IPO Year
- MESO N/A
- RAMP 1987
- Fundamental
- Price
- MESO $18.04
- RAMP $33.05
- Analyst Decision
- MESO Buy
- RAMP Buy
- Analyst Count
- MESO 4
- RAMP 7
- Target Price
- MESO $13.50
- RAMP $39.71
- AVG Volume (30 Days)
- MESO 828.2K
- RAMP 476.9K
- Earning Date
- MESO 02-28-2025
- RAMP 02-06-2025
- Dividend Yield
- MESO N/A
- RAMP N/A
- EPS Growth
- MESO N/A
- RAMP N/A
- EPS
- MESO N/A
- RAMP 0.04
- Revenue
- MESO $5,902,000.00
- RAMP $707,165,000.00
- Revenue This Year
- MESO $65.99
- RAMP $13.82
- Revenue Next Year
- MESO $425.77
- RAMP $9.09
- P/E Ratio
- MESO N/A
- RAMP $756.72
- Revenue Growth
- MESO N/A
- RAMP 13.84
- 52 Week Low
- MESO $1.72
- RAMP $21.45
- 52 Week High
- MESO $22.00
- RAMP $42.10
- Technical
- Relative Strength Index (RSI)
- MESO 59.20
- RAMP 68.43
- Support Level
- MESO $15.92
- RAMP $27.99
- Resistance Level
- MESO $17.67
- RAMP $31.90
- Average True Range (ATR)
- MESO 1.38
- RAMP 0.80
- MACD
- MESO -0.37
- RAMP 0.22
- Stochastic Oscillator
- MESO 37.14
- RAMP 96.75
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About RAMP LiveRamp Holdings Inc.
LiveRamp Holdings Inc is a global technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust.